Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Core Viewpoint - Henan Lingrui Pharmaceutical Co., Ltd. has established itself as a household name in the pain relief patch market through innovative production techniques and product development. Group 1: Production Innovations - The company utilizes smart manufacturing technologies, including self-developed digital extraction equipment, to enhance the efficiency, environmental sustainability, and energy conservation of traditional Chinese medicine extraction [2][3]. - A centralized control center monitors over 300 production data points in real-time, ensuring quality stability across different batches of herbal extracts [3]. - The integration of an intelligent logistics and warehousing system has created a "digital highway" from production to shipping, incorporating advanced technologies such as AGV systems and drug traceability [3]. Group 2: Product Development - Lingrui Pharmaceutical has expanded its product line beyond traditional patches, introducing innovative products like the indomethacin patch, which employs advanced laser micropore technology for enhanced functionality [4]. - The company is actively developing new products, including a novel nasal spray for treating cold symptoms, which is expected to broaden its therapeutic applications and clinical value [5]. - The annual sales of the "Two Tigers" patch series have exceeded 1 billion patches, covering various medical fields such as orthopedics, neurology, respiratory medicine, anesthesiology, dermatology, and pediatrics [5]. Group 3: Investment in R&D - Lingrui Pharmaceutical commits 3% to 5% of its annual revenue to research and development, establishing high-level platforms such as a national enterprise technology center and a postdoctoral research workstation [5]. - The company's approach demonstrates that the heritage of traditional brands can serve as a foundation for innovation, enabling them to navigate market cycles and achieve high-quality growth [5].

Core Insights - The company, Lingrui Pharmaceutical, has established itself as a household name in the production of medicated plasters, leveraging advanced technology and innovation to enhance product quality and production efficiency [1][2][3] Group 1: Production and Technology - Lingrui Pharmaceutical has implemented smart manufacturing systems, including a digital extraction process that ensures the quality stability of traditional Chinese medicine extracts [1] - The company has developed an integrated ERP data platform that connects sales, production, and inventory data, allowing for real-time intelligent production scheduling and energy-efficient operations [2] - The production facility is capable of producing 10,000 medicated plasters per minute, showcasing the efficiency of its smart manufacturing processes [1] Group 2: Product Development and Market Position - The company has expanded its product line through continuous research and development, with its "Two Tigers" medicated plaster series achieving annual sales exceeding 1 billion plasters [3] - Lingrui Pharmaceutical is set to launch a new innovative drug, a nasal spray for treating cold symptoms, which will broaden its therapeutic offerings and enhance clinical value [3] - The company invests 3% to 5% of its annual revenue into research and development, establishing high-level platforms such as a national enterprise technology center and a postdoctoral research workstation [3]

证券代码：600285 证券简称：羚锐制药 公告编号：2026-002 河南羚锐制药股份有限公司 董事减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体减持前基本情况 上述股份来源包括股权激励股份因资本公积转增股本所得。 上述减持主体无一致行动人。 1 披露的减持时间区间届满 重要内容提示： 董事持股的基本情况 河南羚锐制药股份有限公司(以下简称"公司")于 2025 年 9 月 16 日披露了 《 董 事 减 持 股 份 计 划 公 告 》， 具 体 内 容 详 见 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn/）公司公告。截至本公告披露之日，公司董事陈燕女 士持有公司股票 965,000 股，持股比例为 0.17%。 减持计划的实施结果情况 截至本公告披露之日，陈燕女士本次减持计划实施时间届满，其尚未减持公 司股票。 | 股东名称 | 陈燕 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 ...

近日，公司接到羚锐集团股份质押的通知，羚锐集团将其持有的公司无限售 流通股 1,700,000 股质押给中国农业银行股份有限公司新县支行，具体如下： 证券代码：600285 证券简称：羚锐制药 公告编号：2026-003 号 河南羚锐制药股份有限公司 关于大股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 河南羚锐集团有限公司（以下简称"羚锐集团"）持有河南羚锐制药股 份有限公司（以下简称"公司"）股票 121,817,898 股，占公司总股本的 21.48%。 本次质押 1,700,000 股后，羚锐集团累计质押本公司股份 30,050,000 股，占其 持股数量比例为 24.67%，占公司总股本的 5.30%。 截至本公告披露日，羚锐集团及其一致行动人持有本公司股份累计质押 数量为 30,050,000 股，占公司总股本的 5.30%。 一、本次股份质押基本情况 1.本次股份质押基本情况 | | | | | | | | | | 已质押股 | 未质押股 | | | --- | --- | ...

Group 1 - The major shareholder, Lingrui Group, holds 122 million shares of Lingrui Pharmaceutical, accounting for 21.48% of the total share capital [1] - Recently, Lingrui Group pledged 1.7 million unrestricted circulating shares to Agricultural Bank of China for financing purposes, specifically for operational liquidity [1] - After this pledge, Lingrui Group has cumulatively pledged 30.05 million shares, which represents 24.67% of its holdings and 5.30% of the company's total share capital [1] Group 2 - The pledge will not affect the company's operations or lead to any change in control [1]

Core Viewpoint - Lingrui Pharmaceutical's stock has experienced a decline recently, with a slight increase in revenue and net profit year-on-year, indicating potential challenges in market performance despite positive financial growth [1][2]. Group 1: Stock Performance - On January 14, Lingrui Pharmaceutical's stock fell by 2.03%, trading at 20.73 CNY per share, with a total market capitalization of 11.756 billion CNY [1]. - The stock has seen a year-to-date increase of 0.10%, but has declined by 3.36% over the last five trading days, 2.63% over the last 20 days, and 10.03% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Lingrui Pharmaceutical achieved a revenue of 3.041 billion CNY, representing a year-on-year growth of 10.23% [2]. - The net profit attributable to shareholders for the same period was 651 million CNY, reflecting a year-on-year increase of 13.43% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Lingrui Pharmaceutical increased to 42,500, a rise of 25.64% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 20.41% to 13,307 shares [2]. - The company has distributed a total of 2.544 billion CNY in dividends since its A-share listing, with 1.3 billion CNY distributed over the last three years [3].

Group 1 - The core viewpoint of the news highlights the performance of the TaiKang Medical Health Fund, which saw declines in its two share classes, with Class C down by 13.45% and Class A down by 13.02% in 2025 [2][3] - The top ten holdings of the TaiKang Medical Health Fund in the third quarter of 2025 included companies such as JingTai Holdings, Kanglong Chemical, Fangzhou Jianke, SanSheng Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [2] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., and has been with TaiKang since July 2019, becoming the fund manager on March 8, 2022 [2]

Group 1 - The fentanyl concept index rose by 4.74%, ranking 6th among concept sectors, with 8 stocks increasing in value, including Botao Bio which hit a 20% limit up [1] - The leading stocks in the fentanyl sector included Dongfang Bio, Lingrui Pharmaceutical, and ST Renfu, which rose by 5.12%, 4.88%, and 2.26% respectively [1] Group 2 - The fentanyl concept sector saw a net inflow of 55 million yuan, with ST Renfu leading the inflow at 69.89 million yuan, followed by Guoyao Shares, Guoyao Modern, and Lingrui Pharmaceutical [2] - The net inflow ratios for ST Renfu, Guoyao Modern, and Guoyao Shares were 14.70%, 7.69%, and 5.96% respectively, indicating strong interest from major funds [3]

Core Viewpoint - The company has developed an action plan titled "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" to enhance operational quality and competitiveness, aligning with government initiatives and market expectations [1] Group 1: Strategic Focus - The company aims to strengthen its core pharmaceutical business, particularly in orthopedics and cardiovascular fields, while enhancing brand and product category development [2] - Future strategies include optimizing business structure, improving operational efficiency, and advancing product innovation, particularly in transdermal patches [2] - The company plans to upgrade manufacturing capabilities through technological innovations and expand its distribution channels to create a comprehensive national network [2] Group 2: Innovation-Driven Development - The company adheres to an "innovation-driven development" strategy, focusing on product innovation as a key growth engine [3] - It will leverage its research platforms to enhance capabilities in traditional Chinese medicine and advanced formulations, particularly in pain management and chronic disease areas [3] - Increased investment in research and development will target quality control, process improvement, and clinical value exploration [3] Group 3: Governance and Compliance - The company is committed to enhancing its governance structure in accordance with relevant laws and regulations, ensuring the protection of shareholder rights [4] - Plans include strengthening the roles of various board committees and enhancing the decision-making process through independent directors [5] Group 4: Shareholder Return Mechanism - The company emphasizes investor returns, having distributed a total of RMB 2.544 billion in cash dividends since its listing in 2000 [6] - A three-year shareholder return plan (2024-2026) will be established to ensure stable and predictable returns based on operational performance and shareholder expectations [6] Group 5: Investor Relations and Information Disclosure - The company will enhance its information disclosure practices to ensure transparency and timely communication with investors [7] - Efforts will be made to improve investor relations management and actively engage with core investor groups [7] Group 6: Responsibility System for Key Personnel - The company focuses on the management of key personnel, ensuring compliance and enhancing their responsibilities through training and performance evaluation [8] - A robust responsibility system will be established to strengthen compliance awareness and operational effectiveness among key stakeholders [8]